The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
Go back to The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 201.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $201.99 | 52 Week High | $333.65 | |||
| Open | $201.99 | 52 Week Low | $223.02 | |||
| Day High | $201.99 | P/E | 25.86 | |||
| Day Low | $201.99 | EPS | $7.81 | |||
| Volume | 37 | |||||
